Renal anemia: From incurable to curable

American Journal of Physiology - Renal Physiology

Volumn 305, Issue 9, 2013, Pages

  Sato, Yuki ^a   Yanagita, Motoko ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Erythropoietin; Hypoxia inducible factors; Myofibroblast; Neural crest; Renal anemia

Indexed keywords

ANTIANEMIC AGENT; DEXAMETHASONE; GLUCOCORTICOID; HEMOGLOBIN; NEUROTROPHIN; PEGINESATIDE; RALOXIFENE; RECOMBINANT ERYTHROPOIETIN; TAMOXIFEN;

ALZHEIMER DISEASE; ANEMIA; CELL TRANSDIFFERENTIATION; CLINICAL EFFECTIVENESS; GENE EXPRESSION; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; MESENCHYMAL STEM CELL TRANSPLANTATION; MORTALITY; MYOFIBROBLAST; NEUROPROTECTION; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REGENERATIVE MEDICINE; RENAL ANEMIA; RENAL PROTECTION; REVIEW; STEROID THERAPY; UNSPECIFIED SIDE EFFECT;

EID: 84886997570     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00233.2013     Document Type: Review

References (128)

1. Adamson JW. The erythropoietin-hematocrit relationship in normal and polycythemic man: implications of marrow regulation. Blood 32: 597-609, 1968.
2. Artunc F, Risler T. Serum erythropoietin concentrations and responses to anaemia in patients with or without chronic kidney disease. Nephrol Dial Transplant 22: 2900-2908, 2007.
3. Asada N, Takase M, Nakamura J, Oguchi A, Asada M, Suzuki N, Yamamura K, Nagoshi N, Shibata S, Rao TN, Fehling HJ, Fukatsu A, Minegishi N, Kita T, Kimura T, Okano H, Yamamoto M, Yanagita M. Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Invest 121: 3981-3990, 2011.
4. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 162: 1401-1408, 2002.
5. Bamgbola OF. Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease. Kidney Int 80: 464-474, 2011.
6. Baylis C. Age-dependent glomerular damage in the rat. Dissociation between glomerular injury and both glomerular hypertension and hypertrophy. Male gender as a primary risk factor. J Clin Invest 94: 1823-1829, 1994.
7. Bernhardt WM, Wiesener MS, Scigalla P, Chou J, Schmieder RE, Gunzler V, Eckardt KU. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 21: 2151-2156, 2010.
8. Bi B, Guo J, Marlier A, Lin SR, Cantley LG. Erythropoietin expands a stromal cell population that can mediate renoprotection. Am J Physiol Renal Physiol 295: F1017-F1022, 2008.
9. Blumberg A, Keller H, Marti HR. Effect of altitude on erythropoiesis and oxygen affinity in anaemic patients on maintenance dialysis. Eur J Clin Invest 3: 93-97, 1973.
10. Brines M, Cerami A. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int 70: 246-250, 2006.
11. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, Itri LM, Cerami A. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 97: 10526-10531, 2000.
12. Bronner-Fraser M, Fraser SE. Cell lineage analysis reveals multipotency of some avian neural crest cells. Nature 335: 161-164, 1988.
13. Brookhart MA, Schneeweiss S, Avorn J, Bradbury BD, Rothman KJ, Fischer M, Mehta J, Winkelmayer WC. The effect of altitude on dosing and response to erythropoietin in ESRD. J Am Soc Nephrol 19: 1389-1395, 2008.
14. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 100: 4802-4806, 2003.
15. Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 27: 275-280, 2009.
16. Chandra M, Clemons GK, McVicar MI. Relation of serum erythropoietin levels to renal excretory function: evidence for lowered set point for erythropoietin production in chronic renal failure. J Pediatr 113: 1015-1021, 1988.
17. Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci 4: 299-309, 2003.
18. Chenuaud P, Larcher T, Rabinowitz JE, Provost N, Cherel Y, Casadevall N, Samulski RJ, Moullier P. Autoimmune anemia in macaques following erythropoietin gene therapy. Blood 103: 3303-3304, 2004.
19. Chin M, Isono M, Isshiki K, Araki S, Sugimoto T, Guo B, Sato H, Haneda M, Kashiwagi A, Koya D. Estrogen and raloxifene, a selective estrogen receptor modulator, ameliorate renal damage in db/db mice. Am J Pathol 166: 1629-1636, 2005.
20. Cotes PM. Immunoreactive erythropoietin in serum. I. Evidence for the validity of the assay method and the physiological relevance of estimates. Br J Haematol 50: 427-438, 1982.
21. Dame C, Fahnenstich H, Freitag P, Hofmann D, Abdul-Nour T, Bartmann P, Fandrey J. Erythropoietin mRNA expression in human fetal and neonatal tissue. Blood 92: 3218-3225, 1998.
22. Delano BG. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kidney Dis 14: 14-18, 1989.
23. Dixon A, Wells CC, Singh S, Babayan R, Maric C. Renoprotective effects of a selective estrogen receptor modulator, raloxifene, in an animal model of diabetic nephropathy. Am J Nephrol 27: 120-128, 2007.
24. Donnelly S. Why is erythropoietin made in the kidney? The kidney functions as a critmeter. Am J Kidney Dis 38: 415-425, 2001.
25. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084, 2006.
26. Ebert BL, Bunn HF. Regulation of the erythropoietin gene. Blood 94: 1864-1877, 1999.
27. Eckardt KU, Ratcliffe PJ, Tan CC, Bauer C, Kurtz A. Age-dependent expression of the erythropoietin gene in rat liver and kidneys. J Clin Invest 89: 753-760, 1992.
28. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316: 73-78, 1987.
29. Fandrey J. Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. Am J Physiol Regul Integr Comp Physiol 286: R977-R988, 2004.
30. Fehr T, Ammann P, Garzoni D, Korte W, Fierz W, Rickli H, Wuthrich RP. Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia. Kidney Int 66: 1206-1211, 2004.
31. Frede S, Freitag P, Geuting L, Konietzny R, Fandrey J. Oxygenregulated expression of the erythropoietin gene in the human renal cell line REPC. Blood 117: 4905-4914, 2011.
32. Fried W. The liver as a source of extrarenal erythropoietin production. Blood 40: 671-677, 1972.
33. Gao G, Lebherz C, Weiner DJ, Grant R, Calcedo R, McCullough B, Bagg A, Zhang Y, Wilson JM. Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood 103: 3300-3302, 2004.
34. Garcia JF, Ebbe SN, Hollander L, Cutting HO, Miller ME, Cronkite EP. Radioimmunoassay of erythropoietin: circulating levels in normal and polycythemic human beings. J Lab Clin Med 99: 624-635, 1982.
35. Giaccia AJ, Simon MC, Johnson R. The biology of hypoxia: the role of oxygen sensing in development, normal function, and disease. Genes Dev 18: 2183-2194, 2004.
36. Godin I, Cumano A. Of birds and mice: hematopoietic stem cell development. Int J Dev Biol 49: 251-257, 2005.
37. Goldberg MA, Glass GA, Cunningham JM, Bunn HF. The regulated expression of erythropoietin by two human hepatoma cell lines. Proc Natl Acad Sci USA 84: 7972-7976, 1987.
38. Goodkin DA, Fuller DS, Robinson BM, Combe C, Fluck R, Mendelssohn D, Akizawa T, Pisoni RL, Port FK. Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients. J Am Soc Nephrol 22: 358-365, 2011.
39. Grgic I, Duffield JS, Humphreys BD. The origin of interstitial myofibroblasts in chronic kidney disease. Pediatr Nephrol 27: 183-193, 2012.
40. Gross AW, Lodish HF. Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). J Biol Chem 281: 2024-2032, 2006.
41. Gruber M, Hu CJ, Johnson RS, Brown EJ, Keith B, Simon MC. Acute postnatal ablation of Hif-2+ results in anemia. Proc Natl Acad Sci USA 104: 2301-2306, 2007.
42. Haase VH. Hypoxic regulation of erythropoiesis and iron metabolism. Am J Physiol Renal Physiol 299: F1-F13, 2010.
43. Haase VH. Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev 27: 41-53, 2013.
44. Haroun MK, Jaar BG, Hoffman SC, Comstock GW, Klag MJ, Coresh J. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol 14: 2934-2941, 2003.
45. Higgins MR, Grace M, Ulan RA, Silverberg DS, Bettcher KB, Dossetor JB. Anemia in hemodialysis patients. Arch Intern Med 137: 172-176, 1977.
46. Hsieh MM, Linde NS, Wynter A, Metzger M, Wong C, Langsetmo I, Lin A, Smith R, Rodgers GP, Donahue RE, Klaus SJ, Tisdale JF. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood 110: 2140-2147, 2007.
47. Hsu CY, Bates DW, Kuperman GJ, Curhan GC. Relationship between hematocrit and renal function in men and women. Kidney Int 59: 725-731, 2001.
48. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-inducible factor 1+ (HIF-1+) and HIF-2+ in hypoxic gene regulation. Mol Cell Biol 23: 9361-9374, 2003.
49. Humphreys BD, Lin SL, Kobayashi A, Hudson TE, Nowlin BT, Bonventre JV, Valerius MT, McMahon AP, Duffield JS. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 176: 85-97, 2010.
50. Imagawa S, Yamamoto M, Miura Y. Negative regulation of the erythropoietin gene expression by the GATA transcription factors. Blood 89: 1430-1439, 1997.
51. Johnson DW, Pat B, Vesey DA, Guan Z, Endre Z, Gobe GC. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 69: 1806-1813, 2006.
52. Kapitsinou PP, Liu Q, Unger TL, Rha J, Davidoff O, Keith B, Epstein JA, Moores SL, Erickson-Miller CL, Haase VH. Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia. Blood 116: 3039-3048, 2010.
53. Karavanov A, Sainio K, Palgi J, Saarma M, Saxen L, Sariola H. Neurotrophin 3 rescues neuronal precursors from apoptosis and promotes neuronal differentiation in the embryonic metanephric kidney. Proc Natl Acad Sci USA 92: 11279-11283, 1995.
54. Koesters R, Kaissling B, Lehir M, Picard N, Theilig F, Gebhardt R, Glick AB, Hahnel B, Hosser H, Grone HJ, Kriz W. Tubular overexpression of transforming growth factor-α1 induces autophagy and fibrosis but not mesenchymal transition of renal epithelial cells. Am J Pathol 177: 632-643, 2010.
55. Kohagura K, Tomiyama N, Kinjo K, Takishita S, Iseki K. Prevalence of anemia according to stage of chronic kidney disease in a large screening cohort of Japanese. Clin Exp Nephrol 13: 614-620, 2009.
56. Kominami N, Lowrie EG, Ianhez LE, Sakren A, Hampers CL, Merrill JP, Lange RD. The effect of total nephrectomy on hematopoiesis in patients undergoing chronic hemodialysis. J Lab Clin Med 78: 524-532, 1971.
57. Koury MJ, Bondurant MC, Graber SE, Sawyer ST. Erythropoietin messenger RNA levels in developing mice and transfer of 125I-erythropoietin by the placenta. J Clin Invest 82: 154-159, 1988.
58. Koury ST, Bondurant MC, Koury MJ. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood 71: 524-527, 1988.
59. Koury ST, Koury MJ, Bondurant MC, Caro J, Graber SE. Quantitation of erythropoietin-producing cells in kidneys of mice by in situ hybridization: correlation with hematocrit, renal erythropoietin mRNA, and serum erythropoietin concentration. Blood 74: 645-651, 1989.
60. Krapf R, Hulter HN. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). Clin J Am Soc Nephrol 4: 470-480, 2009.
61. Kriz W, Kaissling B, Le Hir M. Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy? J Clin Invest 121: 468-474, 2011.
62. Kurt B, Paliege A, Willam C, Schwarzensteiner I, Schucht K, Neymeyer H, Sequeira-Lopez ML, Bachmann S, Gomez RA, Eckardt KU, Kurtz A. Deletion of von Hippel-Lindau protein converts renin-producing cells into erythropoietin-producing cells. J Am Soc Nephrol 24: 433-444, 2013.
63. Kurtz A, Jelkmann W, Sinowatz F, Bauer C. Renal mesangial cell cultures as a model for study of erythropoietin production. Proc Natl Acad Sci USA 80: 4008-4011, 1983.
64. Lacombe C, Da Silva JL, Bruneval P, Fournier JG, Wendling F, Casadevall N, Camilleri JP, Bariety J, Varet B, Tambourin P. Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest 81: 620-623, 1988.
65. Laitala A, Aro E, Walkinshaw G, Maki JM, Rossi M, Heikkila M, Savolainen ER, Arend M, Kivirikko KI, Koivunen P, Myllyharju J. Transmembrane prolyl 4-hydroxylase is a fourth prolyl 4-hydroxylase regulating EPO production and erythropoiesis. Blood 120: 3336-3344, 2012.
66. Le Douarin NM. The avian embryo as a model to study the development of the neural crest: a long and still ongoing story. Mech Dev 121: 1089-1102, 2004.
67. Le Douarin NM, Teillet MA. Experimental analysis of the migration and differentiation of neuroblasts of the autonomic nervous system and of neurectodermal mesenchymal derivatives, using a biological cell marking technique. Dev Biol 41: 162-184, 1974.
68. Lee EC, Yu D, Martinez de Velasco J, Tessarollo L, Swing DA, Court DL, Jenkins NA, Copeland NG. A highly efficient Escherichia colibased chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA. Genomics 73: 56-65, 2001.
69. Lendahl U, Lee KL, Yang H, Poellinger L. Generating specificity and diversity in the transcriptional response to hypoxia. Nat Rev Genet 10: 821-832, 2009.
70. Li L, Zepeda-Orozco D, Black R, Lin F. Autophagy is a component of epithelial cell fate in obstructive uropathy. Am J Pathol 176: 1767-1778, 2010.
71. Lin CS, Lim SK, D'Agati V, Costantini F. Differential effects of an erythropoietin receptor gene disruption on primitive and definitive erythropoiesis. Genes Dev 10: 154-164, 1996.
72. Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, Chen KK, Fox GM, Martin F, Stabinsky Z, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 82: 7580-7584, 1985.
73. Lin SL, Kisseleva T, Brenner DA, Duffield JS. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 173: 1617-1627, 2008.
74. Liu Y. Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am J Physiol Renal Physiol 287: F7-F16, 2004.
75. Loya F, Yang Y, Lin H, Goldwasser E, Albitar M. Transgenic mice carrying the erythropoietin gene promoter linked to lacZ express the reporter in proximal convoluted tubule cells after hypoxia. Blood 84: 1831-1836, 1994.
76. Macdougall IC. Novel erythropoiesis-stimulating agents: a new era in anemia management. Clin J Am Soc Nephrol 3: 200-207, 2008.
77. Macdougall IC, Ashenden M. Current and upcoming erythropoiesisstimulating agents, iron products, and other novel anemia medications. Adv Chronic Kidney Dis 16: 117-130, 2009.
78. Macdougall IC, Lewis NP, Saunders MJ, Cochlin DL, Davies ME, Hutton RD, Fox KA, Coles GA, Williams JD. Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 335: 489-493, 1990.
79. Madan A, Lin C, Hatch SL, 2nd, Curtin PT. Regulated basal, inducible, and tissue-specific human erythropoietin gene expression in transgenic mice requires multiple cis DNA sequences. Blood 85: 2735-2741, 1995.
80. Marsh JT, Brown WS, Wolcott D, Carr CR, Harper R, Schweitzer SV, Nissenson AR. rHuEPO treatment improves brain and cognitive function of anemic dialysis patients. Kidney Int 39: 155-163, 1991.
81. Mastrogiannaki M, Matak P, Keith B, Simon MC, Vaulont S, Peyssonnaux C. HIF-2+, but not HIF-1+, promotes iron absorption in mice. J Clin Invest 119: 1159-1166, 2009.
82. Maxwell P. HIF-1: an oxygen response system with special relevance to the kidney. J Am Soc Nephrol 14: 2712-2722, 2003.
83. McGonigle RJ, Wallin JD, Shadduck RK, Fisher JW. Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int 25: 437-444, 1984.
84. Melamed ML, Blackwell T, Neugarten J, Arnsten JH, Ensrud KE, Ishani A, Cummings SR, Silbiger SR. Raloxifene, a selective estrogen receptor modulator, is renoprotective: a post-hoc analysis. Kidney Int 79: 241-249, 2011.
85. Misaizu T, Matsuki S, Strickland TW, Takeuchi M, Kobata A, Takasaki S. Role of antennary structure of N-linked sugar chains in renal handling of recombinant human erythropoietin. Blood 86: 4097-4104, 1995.
86. Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. J Biol Chem 252: 5558-5564, 1977.
87. Mole DR, Blancher C, Copley RR, Pollard PJ, Gleadle JM, Ragoussis J, Ratcliffe PJ. Genome-wide association of hypoxia-inducible factor (HIF)-1+ and HIF-2+ DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem 284: 16767-16775, 2009.
88. Morikawa S, Mabuchi Y, Niibe K, Suzuki S, Nagoshi N, Sunabori T, Shimmura S, Nagai Y, Nakagawa T, Okano H, Matsuzaki Y. Development of mesenchymal stem cells partially originate from the neural crest. Biochem Biophys Res Commun 379: 1114-1119, 2009.
89. Moritz KM, Lim GB, Wintour EM. Developmental regulation of erythropoietin and erythropoiesis. Am J Physiol Regul Integr Comp Physiol 273: R1829-R1844, 1997.
90. Nagoshi N, Shibata S, Kubota Y, Nakamura M, Nagai Y, Satoh E, Morikawa S, Okada Y, Mabuchi Y, Katoh H, Okada S, Fukuda K, Suda T, Matsuzaki Y, Toyama Y, Okano H. Ontogeny and multipotency of neural crest-derived stem cells in mouse bone marrow, dorsal root ganglia, and whisker pad. Cell Stem Cell 2: 392-403, 2008.
91. Nangaku M, Eckardt KU. Hypoxia and the HIF system in kidney disease. J Mol Med (Berl) 85: 1325-1330, 2007.
92. Nangaku M, Eckardt KU. Pathogenesis of renal anemia. Semin Nephrol 26: 261-268, 2006.
93. Obara N, Suzuki N, Kim K, Nagasawa T, Imagawa S, Yamamoto M. Repression via the GATA box is essential for tissue-specific erythropoietin gene expression. Blood 111: 5223-5232, 2008.
94. Paliege A, Rosenberger C, Bondke A, Sciesielski L, Shina A, Heyman SN, Flippin LA, Arend M, Klaus SJ, Bachmann S. Hypoxia-inducible factor-2+-expressing interstitial fibroblasts are the only renal cells that express erythropoietin under hypoxia-inducible factor stabilization. Kidney Int 77: 312-318, 2010.
95. Palis J. Ontogeny of erythropoiesis. Curr Opin Hematol 15: 155-161, 2008.
96. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, Pellegrini F, Ravani P, Jardine M, Perkovic V, Graziano G, McGee R, Nicolucci A, Tognoni G, Strippoli GF. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 153: 23-33, 2010.
97. Patapoutian A, Reichardt LF. Trk receptors: mediators of neurotrophin action. Curr Opin Neurobiol 11: 272-280, 2001.
98. Patel NS, Collino M, Yaqoob MM, Thiemermann C. Erythropoietin in the intensive care unit: beyond treatment of anemia. Ann Intensive Care 1: 40, 2011.
99. Peng J, Zhang L, Drysdale L, Fong GH. The transcription factor EPAS-1/hypoxia-inducible factor 2+ plays an important role in vascular remodeling. Proc Natl Acad Sci USA 97: 8386-8391, 2000.
100. Percy MJ, Furlow PW, Lucas GS, Li X, Lappin TR, McMullin MF, Lee FS. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med 358: 162-168, 2008.
101. Quaggin SE, Kapus A. Scar wars: mapping the fate of epithelialmesenchymal-myofibroblast transition. Kidney Int 80: 41-50, 2011.
102. Querbes W, Bogorad RL, Moslehi J, Wong J, Chan AY, Bulgakova E, Kuchimanchi S, Akinc A, Fitzgerald K, Koteliansky V, Kaelin WG Jr. Treatment of erythropoietin deficiency in mice with systemically administered siRNA. Blood 120: 1916-1922, 2012.
103. Sainio K, Nonclercq D, Saarma M, Palgi J, Saxen L, Sariola H. Neuronal characteristics in embryonic renal stroma. Int J Dev Biol 38: 77-84, 1994.
104. Sakamoto S, Igarashi T, Osumi N, Imamoto T, Tobe T, Kamiya M, Ito H. Erythropoietin-producing renal cell carcinoma in chronic hemodialysis patients: a report of two cases. Int J Urol 10: 49-51, 2003.
105. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 5: 343-354, 2004.
106. Schrimpf C, Duffield JS. Mechanisms of fibrosis: the role of the pericyte. Curr Opin Nephrol Hypertens 20: 297-305, 2011.
107. Semenza GL, Dureza RC, Traystman MD, Gearhart JD, Antonarakis SE. Human erythropoietin gene expression in transgenic mice: multiple transcription initiation sites and cis-acting regulatory elements. Mol Cell Biol 10: 930-938, 1990.
108. Semenza GL, Koury ST, Nejfelt MK, Gearhart JD, Antonarakis SE. Cell-type-specific and hypoxia-inducible expression of the human erythropoietin gene in transgenic mice. Proc Natl Acad Sci USA 88: 8725-8729, 1991.
109. Shah YM, Matsubara T, Ito S, Yim SH, Gonzalez FJ. Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. Cell Metab 9: 152-164, 2009.
110. Silberberg J, Racine N, Barre P, Sniderman AD. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 6: 1-4, 1990.
111. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D. Anaemia of CKD-the CHOIR study revisited. Nephrol Dial Transplant 22: 1806-1810, 2007.
112. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006.
113. Suzuki N, Obara N, Pan X, Watanabe M, Jishage K, Minegishi N, Yamamoto M. Specific contribution of the erythropoietin gene 3= enhancer to hepatic erythropoiesis after late embryonic stages. Mol Cell Biol 31: 3896-3905, 2011.
114. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-872, 2007.
115. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-676, 2006.
116. Tan CC, Eckardt KU, Firth JD, Ratcliffe PJ. Feedback modulation of renal and hepatic erythropoietin mRNA in response to graded anemia and hypoxia. Am J Physiol Renal Fluid Electrolyte Physiol 263: F474-F481, 1992.
117. Tanaka T, Nangaku M. Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents. Exp Cell Res 318: 1068-1073, 2012.
118. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 11: 72-82, 1997.
119. Verhelst D, Rossert J, Casadevall N, Kruger A, Eckardt KU, Macdougall IC. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet 363: 1768-1771, 2004.
120. Webster NJ, Pirrung MC. Small molecule activators of the Trk receptors for neuroprotection. BMC Neurosci 9, Suppl 2: S1, 2008.
121. Wenger RH, Hoogewijs D. Regulated oxygen sensing by protein hydroxylation in renal erythropoietin-producing cells. Am J Physiol Renal Physiol 298: F1287-F1296, 2010.
122. Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 83: 59-67, 1995.
123. Yamashita T, Ohneda O, Sakiyama A, Iwata F, Ohneda K, Fujii-Kuriyama Y. The microenvironment for erythropoiesis is regulated by HIF-2+ through VCAM-1 in endothelial cells. Blood 112: 1482-1492, 2008.
124. Yokoo T, Fukui A, Matsumoto K, Ohashi T, Sado Y, Suzuki H, Kawamura T, Okabe M, Hosoya T, Kobayashi E. Generation of a transplantable erythropoietin-producer derived from human mesenchymal stem cells. Transplantation 85: 1654-1658, 2008.
125. Yokoo T, Ohashi T, Shen JS, Sakurai K, Miyazaki Y, Utsunomiya Y, Takahashi M, Terada Y, Eto Y, Kawamura T, Osumi N, Hosoya T. Human mesenchymal stem cells in rodent whole-embryo culture are reprogrammed to contribute to kidney tissues. Proc Natl Acad Sci USA 102: 3296-3300, 2005.
126. Zeisberg M, Duffield JS. Resolved: EMT produces fibroblasts in the kidney. J Am Soc Nephrol 21: 1247-1253, 2010.
127. Zheng F, Plati AR, Potier M, Schulman Y, Berho M, Banerjee A, Leclercq B, Zisman A, Striker LJ, Striker GE. Resistance to glomerulosclerosis in B6 mice disappears after menopause. Am J Pathol 162: 1339-1348, 2003.
128. Zhu X, Perazella MA. Nonhematologic complications of erythropoietin therapy. Semin Dial 19: 279-284, 2006.